SCHEMBL26732575

SCHEMBL26732575

Brc1ccc2c(Br)nnc(Br)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.39
PDPK1 O15530 2/20 0.39
FLT3 P36888 3/20 0.35
CHEK1 O14757 2/20 0.35
PIM1 P11309 2/20 0.35
PRKD3 O94806 2/20 0.35
MAP4K4 O95819 2/20 0.35
CSF1R P07333 2/20 0.35
CLK2 P49760 2/20 0.35
MAP4K2 Q12851 2/20 0.35
DYRK1A Q13627 2/20 0.35
NTRK3 Q16288 2/20 0.35
AURKB Q96GD4 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
METAP2 P50579 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16158369 0.74 CYP2A6 (0.47) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL24076903 0.72 PRMT5 (0.48) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL2462679 0.72 ALOX15 (0.42) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL3260315 0.71 GPR3 (0.45) HTTCYP2A6
SCHEMBL6367202 0.70 PABPC1 (0.50) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL11518864 0.70 PABPC1 (0.50) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL11157400 0.70 ALDH1A1 (0.42) CYP2A6
SCHEMBL2459267 0.70 HTT (0.41) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL25141682 0.70 JAK2 (0.36) JAK2PDPK1FLT3CHEK1PIM1
SCHEMBL23667650 0.69 DHODH (0.41) FLT3CHEK1PIM1ALKAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
EP-4196125-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-06-21 EP disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 CN disclosed
WO-2022036204-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 JAK2 3308/4885PDPK1 2725/4885FLT3 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.